<i>In Situ</i> Self-Assembled Phytopolyphenol-Coordinated Intelligent Nanotherapeutics for Multipronged Management of Ferroptosis-Driven Alzheimer’s Disease-Reference-Cited by-同舟云学术

In Situ Self-Assembled Phytopolyphenol-Coordinated Intelligent Nanotherapeutics for Multipronged Management of Ferroptosis-Driven Alzheimer’s Disease

Published:2024-03-06 Issue:11 Volume:18 Page:7890-7906
ISSN:1936-0851
Container-title:ACS Nano
language:en
Short-container-title:ACS Nano

Author:

Liu Yining¹,Zhao Dongju²^ORCID,Yang Fan¹,Ye Caihua²,Chen Ziyao¹,Chen Yihan²,Yu Xiaomeng¹,Xie Jiyao¹,Dou Yan²^ORCID,Chang Jin¹^ORCID

Affiliation:

1. School of Life Sciences, Tianjin University, Tianjin 300072, People’s Republic of China

2. Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin 300052, People’s Republic of China

Funder

Natural Science Foundation of Tianjin Municipality

National Key Clinical Specialty Discipline Construction Program of China

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsnano.3c09286

Reference49 articles.

1. Twenty-seven-year time trends in dementia incidence in Europe and the United States

2. Alzheimer's disease

3. Recent progress in multifunctional metal chelators as potential drugs for Alzheimer's disease

4. Simultaneous Fe ²⁺ /Fe ³⁺ imaging shows Fe ³⁺ over Fe ²⁺ enrichment in Alzheimer’s disease mouse brain

5. Iron Metabolism, Ferroptosis, and the Links With Alzheimer’s Disease

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carrier-Free Nanodrugs: From Bench to Bedside;ACS Nano;2024-08-20

2. A Ferroptosis‐Inhibitive Polypeptosome for Synergistic Management of Acute Kidney Injury Through Antioxidation and Iron Binding;Advanced Functional Materials;2024-08-11

3. Nanomedicines Targeting Ferroptosis to Treat Stress-Related Diseases;International Journal of Nanomedicine;2024-08

4. Nanodrug Delivery Systems for Myasthenia Gravis: Advances and Perspectives;Pharmaceutics;2024-05-11